SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced additional restructuring actions to prioritize revenue growth, streamline operations and further reduce overall operating expenses. The Company has continued to rigorously evaluate its growth opportunities and operations, while dedicating substantially all of its resources to growing reimbursed DermTech Melanoma Test (DMT) ...

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from a study evaluating the foundational gene expression assay component of the DermTech Melanoma Test (DMT) across all skin types in the real-world clinical setting. The peer-reviewed study entitled, “ Non-invasive gene expression analysis rules out melanoma with high negative predictive value regar ...

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that it will discontinue the optional TERT promoter mutation add-on assay for its DermTech Melanoma Test (DMT) effective March 1, 2024. Multiple studies, including the Company’s recently completed Trust 2 Study, demonstrated the DMT’s negative predictive value (NPV) to be 99% or higher. A high NPV for a rule-out test provi ...

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from its Trust 2 Study, which evaluated the foundational gene expression assay component of the DermTech Melanoma Test (DMT) in a real-world clinical setting. “ The Trust 2 Study results reaffirm the DMT’s real-world clinical utility to rule out melanoma with a negative predictive value (NPV) that i ...

DermTech, Inc. (NASDAQ:DMTK) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Steve Kunszabo - Head, IR Kevin Sun - CFO Thomas Flaten - Lake Street Capital Markets Alex Nowak - Craig-Hallum Jacob Johnson - Stephens Ladies and gentlemen, thank you for standing by. Welcome to DermTech's Third Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. Please be ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________ FORM 10-Q ________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 ________________________ DERMTECH, INC. (Exact Name ...

Company Participants Bret Christensen - President & Chief Executive Officer Conference Call Participants DermTech, Inc. (NASDAQ:DMTK) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Steve Kunszabo - Head, Investor Relations Kevin Sun - Chief Financial Officer Fourth quarter of 2023 will be the benchmark moving forward and will set a new run rate for operating expenses. We expect that the third quarter of 2023 may have limited costs from winding down certain programs. Net loss for the second quart ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________ FORM 10-Q ________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 ________________________ DERMTECH, INC. (Exact Name of R ...

Yes, Mason. Hey, thanks. So, we have implemented what we call kind of a Phase 2 of that EMR integration, which is the EMR thatÂ's used by the most dermatologists. And that integration allows us to more easily get medical records from the physician and relieve the burden of the physicianÂ's offices of having to do that. So that obviously plays into the strategy where the more medical records we get, the more appeals that we can file and have a higher likelihood of success of those appeals. And it lays into o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 ________________________ DERMTECH, INC. WASHINGTON, DC 20549 ________________________ FORM 10-Q ________________________ Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 (Exact Name of R ...